PNV - Banter and General Comments, page-7788

Polynovo are tackling some hard medical cases. if they can proove viable solutions the world is their oyster

several companies have tried hernia solutions that tear and are having massive lawsuits and big payouts
i read johnson and johnson wound repair division has paid hundreds of millions for their vaginal mesh product that fda have now made a class 3 medical device (high risk). diabetic ulcers is a tough problem to solve too

if polynovo can proove just one of these hernia or diabetic ulcers it opens up a huge additional market to sell to (in addition to what BTM is already playing in)

if surgeons are finding new novel ways to use btm each time they do that you could estimate the size of that market

i think pnv rolling cash back into growth would be getting a huge ROI at this stage far better than dividend pay outs and the benefit to shareholders is a high growth stock with ever increasing shareprice- no dividends but still very good returns


do we know many health companies paying dividends? and then see when they started paying dividends. double triple and quadruple the sales force first before any dividends. they are selling BTM now, and then as soon as a new product comes out they already have the sales team, the networks. and prooven story of BTM to walk in and then talk hernia, or cardiac valves, or skin for pancreas cell replacement, diabetic ulcers etc... thats when itll really scale the business. BTM is setting the business up. new products that come out will help establish it as a global wound brand